One Case of Thrombocytopenia and Leukopenia Induced by Teicolanin and Rebabapide

doi:10.19803/j.1672-8629.20240455

Abstract

Abstract: Objective To investigate the clinical characteristics and possible mechanism of thrombocytopenia and leukopenia induced by teicoplanin and rebamipide and provide a reference for safe clinical use. Methods One case of thrombocytopenia and leukopenia induced by teicoplanin and rebamipide was reported. Based on related literature, the mechanism of adverse reactions was analyzed. Results The patient experienced thrombocytopenia and leukopenia after using teicoplanin and rabamipide for 2 days respectively. Clinical pharmacists traced the patient's medications and consulted the drug instructions and related literature before they concluded that thrombocytopenia was related to teicolanin, and leukopenia to rebabapide. Therefore, they recommended that these two drugs be discontinued. Eight days and four days after discontinuation of teicoplanin and rebamipide, respecvtively, platelet transfusion was given and the platelet and white blood cell counts gradually returned to normal. Conclusion Clinicians are to be alert to the risk of such adverse reactions as thrombocytopenia and leukopenia caused by teicoplanin and rebamipide. In case of adverse reactions, related drugs should be discontinued promptly and symptomatic treatment should be given to ensure safe medication.

Key words: Teicoplanin, Rebamipide, Thrombocytopenia, Leukopenia, Adverse Drug Reaction

CLC Number:

R973
R994.11

KOU Jiejian, WANG Yangai. One Case of Thrombocytopenia and Leukopenia Induced by Teicolanin and Rebabapide[J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 227-230.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20240455

https://zgywjj.magtechjournal.com/EN/Y2025/V22/I2/227

References

[1] CHOI JS, YOON SH, PARK HJ, et al.Optimal Use and Need for Therapeutic Drug Monitoring of Teicoplanin in Children: a Systematic Review[J]. Journal of Korean Medical Science, 2023, 38(7): e62.
[2] WATANABE E, MATSUMOTO K, IKAWA K, et al.Pharmacokinetic/Pharmacodynamic Evaluation of Teicoplanin Against Staphylococcus Aureus in a Murine Thigh Infection Model[J]. Journal of Global Antimicrobial Resistance, 2021, 24: 83-87.
[3] FAN WF, MA YH, ZHU YH, et al.Clinical Evaluation of Teicoplanin and Vancomycin in the Treatment of Gram-Positive Bacteria Infection[J]. Electronic Journal of Modern Medicine and Health Research(现代医学与健康研究电子杂志), 2024, 8(5): 33-35.
[4] YAMAGUCHI R, YAMAMOTO T, OKAMOTO K, et al.Teicoplanin and Vancomycin as Treatment for Glycopeptide-Susceptible Enterococcus Faecium Bacteraemia: a Propensity Score-Adjusted Non-Inferior Comparative Study[J]. The Journal of antimicrobial chemotherapy, 2023, 78(5): 1231-1240.
[5] UCGUL AY, BEHCET M.Comparison of the Effect of Teicoplanin and Vancomycin on Experimental Methicillin-Resistant Staphylococcus Aureus Keratitis[J]. Int Ophthalmol, 2021, 41(4): 1395-1402.
[6] KIM GH, LEE HL.Efficacy of Fexuprazan Compared with Rebamipide in Korean Patients with Gastritis: a Matching-Adjusted Indirect Comparison[J]. World Journal of Clinical Cases, 2024, 12(19): 3890-3897.
[7] OH DJ, YOON H, KIM HS, et al.The Effect of Rebamipide on Non-Steroidal Anti-Inflammatory Drug-Induced Gastro-Enteropathy: a Multi-Center, Randomized Pilot Study[J]. The Korean journal of internal medicine, 2022, 37(6): 1153-1166.
[8] WANG JT, WU HS, WENG CM, et al.Prognosis of Patients with Methicillin-Resistant Staphylococcus Aureus Bloodstream Infection Treated with Teicoplanin: a Retrospective Cohort Study Investigating Effect of Teicoplanin Minimum Inhibitory Concentrations[J]. BMC infectious diseases, 2013, 13: 182.
[9] GRANINGER W, PRESTERL E, WENISCH C, et al.Management of Serious Staphylococcal Infections in the Outpatient Setting[J]. Drugs, 1997, 54(Suppl 6): 21-28.
[10] LIU XC, WANG C, ZHANG Y.Literature analysis of Systemic Injury Adverse Reactions Induced by Teicoplanin[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2019, 39(22): 2319-2323.
[11] WANG B.Countermeasures and Clinical Rational Use of Teicoplanin for Severe Adverse Reactions[J]. Chinese Medical Guide(中国医药指南), 2020, 18(29): 30-31.
[12] ASAI Y, YAMAMOTO T, ABE Y.Evaluation of the Expression Profile of Antibiotic-Induced Thrombocytopenia Using the Japanese Adverse Drug Event Report Database[J]. International Journal of Toxicology, 2021, 40(6): 542-550.
[13] YAMADA T, KUBOTA T, NAKAMURA M, et al.Evaluation of Teicoplanin Concentrations and Safety Analysis in Neonates[J]. International journal of Antimicrobial Agents, 2014, 44(5): 458-462.
[14] NIE XL, JIA LL, PENG XX, et al.Detection of Drug-Induced Thrombocytopenia Signals in Children Using Routine Electronic Medical Records[J]. Frontiers in pharmacology, 2021, 12: 756207.
[15] GARNER SF, CAMPBELL K, SMITH G, et al.Teicoplanin-Dependent Antibodies: Detection and Characterization[J]. British Journal of Haematology, 2005, 129(2): 279-281.
[16] SALIMI A, TALAIE H, REZAIE HM, et al.Teicoplanin as an Anti-Methicillin Resistant Staphylococcus Aureus Agent in Infections of Severely Poisoned Intensive Care Unit Patients/ Tehran- Iran[J]. Acta Bio-Medica : Atenei Parmensis, 2014, 84(3): 189-195.
[17] LI XD, CHENG GY, KAN Q, et al.Analysis of a Case Suspected to be Teicolanin Induced Thrombocytopenia[J]. Chinese Pharmacist(中国药师), 2019, 22(2): 305-308.
[18] CHOI HM, CHOI MH, YANG YW.A Case of Teicoplanin-Induced Pancytopenia Caused by Excessive Dosing[J]. American Journal of therapeutics, 2016, 23(1): e307-e310.
[19] HUANG QH, ZHANG RC.Clinical Nursing of 48 Patients with Gram-Positive Coccal Infection Treated with Teicoplanin[J]. Qilu Nursing Journal(齐鲁护理杂志), 2013, 19(21): 98-100.
[20] CHU M, XU ZH, JIANG Q.Thrombocytopenia Induced by Teicoplanin[J]. Journal of Adverse Drug Reactions(药物不良反应杂志), 2012, 14(1): 47-48.
[21] GUO TT.Leukopenia and Thrombocytopenia Induced by Teicoplanin for Injection: a Case Report[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2016, 13(2): 119.
[22] SHAO JM, WANG XG, YU CH, et al.A case of Teicolanin Hypersensitivity Syndrome in Patients with Diabetic Foot Malignant Ulcer[J]. Chinese Journal of Burn(中华烧伤杂志), 2019, 36(8): 747-750.
[23] DEL FA, PATOIA L, BUCANEVE G, et al.Leukopenia with Neutropenia Associated with Teicoplanin Therapy[J]. DICP : the Annals of Pharmacotherapy, 1989, 23(1): 45-47.
[24] ELAJEZ R, ABDALLAH I, BAKDACH D, et al.Thrombocytopenia Associated with Teicoplanin Use: a Retrospective Observational Study[J]. The Annals of Pharmacotherapy, 2022, 56(11): 35179076.
[25] ZHANG X, QU JC, ZHAO Q, et al.Analysis of Hyponatremia Caused by Venlafaxine Hydrochloride Sustained Release Capsule: a Case Report[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2024, 21(7): 819-821.
[26] BELOK SH, BOSCH NA, KLINGS ES, et al.Evaluation of Leukopenia during Sepsis as a Marker of Sepsis-Defining Organ Dysfunction[J]. PLoS One, 2021, 16(6): e0252206.
[27] FOGAGNOLO A, CAMPO GC, MARI M, et al.The Underestimated Role of Platelets in Severe Infection a Narrative Review[J]. Cells, 2022, 11(3): 424.
[28] MARINI I, UZUN G, JAMAL K, et al.Treatment of Drug-Induced Immune Thrombocytopenias[J]. Haematologica, 2022, 107(6): 1264-1277.
[29] TEROL MJ, SIERRA J, GATELL JM, et al.Thrombocytopenia Due to Use of Teicoplanin[J]. Clinical Infectious Diseases, 1993, 17(5): 927.
[30] CHEN GY.Literature Analysis of 23 Cases of Adverse Reactions Caused by Teicoplanin[J]. Chinese Journal of Rural Medicine and Pharmacy(中国乡村医药), 2016, 23(3): 49-51.
[31] LEE JH, CHOI MG, PARK HJ, et al.Comparison of Mortality and Clinical Failure Rates Between Vancomycin and Teicoplanin in Patients with Methicillin-Resistant Staphylococcus Aureus Pneumonia[J]. BMC Infectious Diseases, 2022, 22(1): 600.
[32] NIE XL, MA JY, SUN F, et al.The Pathogenesis and Diagnosis of Drug-Induced Thrombocytopenia[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2024, 21(7): 829-835.